Correction

An article on Dendreon Corp. in the Jan. 14, 2002, edition of BioWorld Today inaccurately stated the status of clinical trials of Mylovenge. Mylovenge is the subject of three Phase II trials. Also, the article should have said Dendreon received a $10 million payment from Kirin Brewery Co. Ltd. when their deal was expanded.

Editor’s note: The correction will me made today in BioWorld Online.